Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma

Abstract excerpt

Abstract MYD88 mutations are one of the most recurrent mutations in hematologic malignancies. However, recent mouse models suggest that MYD88L265P alone may not be sufficient to induce tumor formation. Interplay between MYD88L265P and other genetic events is further supported by the fact that TNFAIP3 (A20) inactivation often accompanies MYD88L265P. However, we are still lacking information about the consequence...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Lymphocytic Leukemia Research
• Share to Lymphoma Diagnosis and Treatment
• Share to NF-κB Signaling Pathways